Have a patient with sickle cell disease?
The purpose of the Hibiscus Study™ is to assess the safety and efficacy of the oral, once-daily investigational medicine (etavopivat) in adolescents and adults with SCD compared with placebo. Efficacy will be measured by hemoglobin (Hb) response and annualized vaso-occlusive crisis (VOC) rate. Etavopivat is a potent, selective, small-molecule activator of pyruvate kinase–red blood cell (PKR).
Hibiscus Study research sites
If you have a patient who may be interested in participating, and you think he or she may qualify, refer your patient to this study website to take the prescreening questionnaire to determine eligibility or fill out a contact request form if you would like to request contact directly from an active research site.